CompletedPhase 2NCT00003575

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Lawrence D. Kaplan, MD
University of California, San Francisco
Intervention: filgrastim(biological)
Enrollment: 40 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 1999

Study locations (10)

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
San Francisco General Hospital Medical Center, San Francisco, California, United States
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
University Hospital/New Jersey Cancer Center, Newark, New Jersey, United States
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Mount Sinai School of Medicine, New York, New York, United States
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00003575 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials